1. Mok, Tony S K, Wu, Yi-Long, Kudaba, Iveta, Kush, Debra, Lopes, Gilberto. 2019. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. In Lancet (London, England), 393, 1819-1830. doi:10.1016/S0140-6736(18)32409-7. https://pubmed.ncbi.nlm.nih.gov/30955977/
2. Garcia-Diaz, Angel, Shin, Daniel Sanghoon, Moreno, Blanca Homet, Lo, Roger S, Ribas, Antoni. . Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression. In Cell reports, 19, 1189-1201. doi:10.1016/j.celrep.2017.04.031. https://pubmed.ncbi.nlm.nih.gov/28494868/
3. Tang, Nana, Yang, Yang, Xie, Yifei, Liu, Zeyi, Huang, Jian-An. 2024. CD274 (PD-L1) negatively regulates M1 macrophage polarization in ALI/ARDS. In Frontiers in immunology, 15, 1344805. doi:10.3389/fimmu.2024.1344805. https://pubmed.ncbi.nlm.nih.gov/38440722/
4. Miyazawa, Masanori, Yamamoto, Yuichiro, Katayama, Kazuhiro, Sugimoto, Yoshikazu, Noguchi, Kohji. 2022. Kaposi's sarcoma-associated herpesvirus replication and transcription activator protein activates CD274/PD-L1 gene promoter. In Cancer science, 114, 1718-1728. doi:10.1111/cas.15673. https://pubmed.ncbi.nlm.nih.gov/36411531/
5. Yang, Lu-Qi, Qin, Zhen, Fu, Lu, Xu, Wang-Dong. . Relationship between CD274 gene polymorphism and systemic lupus erythematosus risk in a Chinese Han population. In International journal of rheumatic diseases, 27, e15026. doi:10.1111/1756-185X.15026. https://pubmed.ncbi.nlm.nih.gov/38287556/
6. Sakran, Mohamed I, Alalawy, Adel I, Alharbi, Amnah A, Toraih, Eman A, Elshazli, Rami M. 2023. The blockage signal for PD-L1/CD274 gene variants and their potential impact on lung carcinoma susceptibility. In International immunopharmacology, 125, 111180. doi:10.1016/j.intimp.2023.111180. https://pubmed.ncbi.nlm.nih.gov/37939515/
智鼠故事 
